Luye Pharma Group Ltd. Completes US Phase II Trial of Cardiovascular TCM
Published: Feb 19, 2013
February 18, 2013 -- Luye Pharma Group reported its Xuezhikang drug, a TCM used to lower cholesterol, proved effective in a US Phase II clinical trial. According to the company, the drug “significantly” lowered low-density lipoprotein cholesterol while elevating beneficial high-density lipoprotein cholesterol. The company did not disclose specific data from the trial. Xuezhikang is the only TCM included in the National Basic List as a treatment for blood lipids. More details....
Stock Symbol: (SGX: A61)